Conference report: Seqirus presents first-of-its-kind study on cell-based quadrivalent influenza vaccine (QIVc) efficacy in children ≥2 to <18 years old

Company presented absolute efficacy data from RCT which met its primary endpoint in children between ≥2 to <18 years of age over three influenza seasons. This study represents the first absolute efficacy study of a cell-based seasonal influenza vaccine in this population.

SPS commentary:

In UK and EU, QIVc is marketed as Flucelvax Tetra and is currently licensed for use in people 9 years of age and older. The results of this study will be used to support applications to national regulatory bodies such as FDA and European Medicines Agency for an expanded age indication in children ≥2 years of age.

Biospace Inc.